DLA Piper: Still in "Growth Mode", Seeking "Escape Velocity"
Harley Lewin of McCarter & English discusses the leading issues facing global brands today
Emerging Markets: Opportunity, Risk, and What it Means for Brand Protection
gTLD Update for September 2013
What is Licensed Property? By Richard Hsu
What is a domain name? Is it the same as a company name?
Trademark Licensing: What You Need to Know
Trademark Series: Protecting your mark from becoming generic
Trademark Series: Matching your commercial strategy
Trademark Series: Building a global brand
Last week, a federal district court in Illinois held that GlaxoSmithKline (GSK), a branded drug manufacturer, owed a duty of care to a patient who took the generic version of its drug. Dolin v. SmithKline Beecham Corp., No....more
The China Trade Marks Office (CTMO) recently announced that from 1 January 2013 it is accepting applications to register trade marks in relation to retail or wholesale services for pharmaceutical, veterinary and sanitary...more
Since passage of the Hatch-Waxman Act in 1984, generic drug companies have used its Abbreviated New Drug Application (ANDA) process to bring cheaper versions of brand-name drugs to market after their patents expire. In the...more
When the Supreme Court decided Mensing, we imagine generic drug manufacturers felt like Stephen Sondheim’s “Everything’s Coming Up Roses” was written just for them. But, to borrow from another Broadway hit, they may now be...more
Back to Top